CHANGES IN PLASMA CYTOKINE LEVELS BEFORE AND AFTER LATENT TUBERCULOSIS INFECTION TREATMENT IN MAINTENANCE HEMODIALYSIS PATIENTS

Thanh Tung Nguyen1, , Ba Thang Ta1, Quoc Toan Pham1, Ngoc Tuan Nguyen2, The Hai Phung2, Hoang Cuong Nguyen1, Ba Nghia Phan1
1 Military Hospital 103
2 Vietnam Military Medical University

Main Article Content

Abstract

Objectives: To evaluate changes in plasma cytokine concentrations of IFN-γ, TNF-α, IL-6, and CXCL-10 in end-stage renal disease (ESRD) patients on maintenance hemodialysis with latent tuberculosis infection (LTBI) after 3 months of treatment. Methods: A descriptive longitudinal study was conducted on 33 ESRD on maintenance hemodialysis with LTBI treated at Military Hospital 103 from August 2023 to December 2025. Plasma cytokine levels were quantified using the ELISA method before and after LTBI treatment. Patients with LTBI received the 3RH regimen and were reassessed after 3 months. Results: After 3 months of LTBI treatment, TNF-α levels and IL-6 levels showed a decreasing trend compared with baseline from 23.10 to 20.80 pg/mL and from 3.20 to 1.41 pg/mL, respectively; however, the differences were not statistically significant (p > 0.05). IFN-γ and CXCL-10 levels showed minimal changes after treatment. In the subgroup of patients with QuantiFERON-TB (QFT) conversion from positive to negative, TNF-α levels decreased significantly after treatment (from 18.40 to 4.69 pg/mL; p = 0.027). Conclusion: After 3 months of LTBI treatment in hemodialysis patients, there was no statistically significant change in plasma levels of IFN-γ, TNF-α, IL-6, and CXCL-10; however, a statistically notable reduction in TNF-α levels was observed in patients with QFT conversion from positive to negative.

Article Details

References

1. Ogawa Y, Harada M, Hashimoto K, et al. Prevalence of latent tuberculosis infection and its risk factors in Japanese hemodialysis patients. Clinical Experimental Nephrology. 2021; 25(11):1255-1265.
2. World Health Organization. Global tuberculosis report 2025. Geneva: World Health Organization. 2025.
3. Xu F, Ni M, Qu S, et al. Molecular markers of tuberculosis and their clinical relevance: A systematic review and meta-analysis. Annals of Palliative Medicine. 2022; 11(2):53243-53543.
4. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024; 105(4 Suppl):S1-S350.
5. Marks GB, Nhung NV, Nguyen T, et al. Prevalence of latent tuberculous infection among adults in the general population of Ca Mau, Viet Nam. The International Journal of Tuberculosis Lung Disease. 2018; 22(3):246-251.
6. Zhou G, Guo X, Cai S, et al. Diabetes mellitus and latent tuberculosis infection: an updated meta-analysis and systematic review. BMC Infectious Diseases. 2023; 23(1):770.
7. Chen J, Hubbard A, Bagley L, et al. Prevalence of latent tuberculosis infection among persons with chronic hepatitis B virus infection: A systematic review and meta-analysis. Digestive Diseases Sciences. 2022; 67(6):2646-2654.
8. Clifford V, Tebruegge M, Zufferey C, et al. Mycobacteria-specific cytokine responses as correlates of treatment response in active and latent tuberculosis. Journal of Infection. 2017; 75(2):132-145.
9. Kireev FD, Lopatnikova JA, Alshevskaya AA, et al. Role of tumor necrosis factor in tuberculosis. Biomolecules. 2025; 15(5):709.
10. Cao X, Xin H, Zhang H, et al. The association between mycobacteria-specific antigen-induced cytokines and host response to latent tuberculosis infection treatment in a Chinese population. Frontiers in Microbiology. 2021; 12:716900.